This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van Hoek, M. Articles by Feelders, R. A. Search for Related Content PubMed PubMed Citation Articles by van Hoek, M. Articles by Feelders, R. A. Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid, in Vivo and in Vitro Studies

Departments of Internal Medicine (M.v.H., L.J.H., P.M.v.K., S.W.J.L., A.J.v.d.L., W.W.d.H., R.A.F.), of Clinical Chemistry (Y.B.d.R.), and of Pathology (F.H.v.N., R.R.d.K.), Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: M. van Hoek, M.D., Department of Internal Medicine–Bd289, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: m.vanhoek{at}erasmusmc.nl.

Context: A 56-yr-old woman presented with acromegaly, a pulmonary mass, and elevated levels of GHRH, GH, and IGF-I. Histological examination revealed a bronchial carcinoid with positive staining for GHRH. Somatostatin analogs (SAs) can play an important role in the treatment of neuroendocrine tumors, dependent on the somatostatin receptor subtype (sst) expression pattern. The sst pattern in bronchial carcinoids and effects of SAs have not been extensively investigated, particularly not for the recently developed universal SA SOM230 (Pasireotide) that has high affinity for sst₁, ₂, ₃, and ₅.

Objective: Our objective was to investigate the in vivo response of a GHRH-producing bronchial carcinoid to octreotide (OCT), its sst-expression profile, and in vitro responses to different SAs, including SOM230.

Methods: In vivo, 50 µg OCT was administered, and plasma GH and GHRH responses were determined. In vitro, the expression of ssts was analyzed by quantitative PCR. Furthermore, the effects of SOM230 and OCT on GHRH secretion were evaluated in primary cell cultures of the carcinoid tissue.

Results: In vivo, OCT administration fully suppressed GH and GHRH levels. In vitro, sst₁ mRNA was most abundant, followed by sst₂ and sst₅. Both SOM230 and OCT inhibited GHRH production dose dependently (SOM230 100 nM vs. control, P = 0.01; OCT 110 nM vs. control, P = 0.05).

Conclusions: In this case of a GHRH-producing bronchial carcinoid, we demonstrated that SOM230 was a potent inhibitor of GHRH production in vitro and was at least equally potent compared with OCT. Therefore, SOM230 may be a potential therapeutic agent to control GHRH secretion in ectopic acromegaly.